Genetron Health

Genetron Health (Chinese: 泛生子; pinyin: Fànshēngzǐ;NASDAQ GTH) is a leading cancer precision medicine company in China. focusing on cancer genomics research and applications, and is committed to changing the way of cancer diagnosis and treatment relying on advanced molecular biology and big data analysis capabilities.
Genetron Health was founded in 2013, headquartered in Beijing, China.
In October 2015, Genetron Biotech's R&D center in the North Carolina Triangle Park was officially opened, and A round of financing was implemented.
On June 28, 2016, Beijing Genetron Health Technology Co., Ltd. and Thermo Fisher Scientific signed a strategic cooperation agreement to jointly build a precision medicine joint research and development center and implement Series B financing.
 
In 2017, 3 IVD products (Genetron 3D Biochip Reader, Human IDH1 Gene Mutation Detection Kit and Human TERT Gene Promoter Mutation Detection Kit) were approved by China Food and Drug Administration.
On March 12, 2019, the Proceedings of the National Academy of Sciences (PNAS) published a collaboration between the National Cancer Center/Tumor Hospital of the Chinese Academy of Medical Sciences and Beijing Genetron Gene Technology Co., Ltd. (Genetic Gene Technology Co., Ltd.), based on cell-free DNA (CfDNA) and protein markers in a prospective cohort of hepatitis B virus carriers for early screening of liver cancer. After rigorous clinical verification, this result is expected to be used in early screening of liver cancer. Its core service "one-step method" has obtained an invention patent, and the gene tester GENETRON S5 and the fully automatic detailed system GENETRON Chef are on the market.
On November 22, 2019, Genetron Health announced that it has completed a new round of financing of more than 500 million yuan, which is used to deepen the translational medicine research, product development and commercialization of the three major business areas of cancer early screening, diagnosis and monitoring, and pharmaceutical service. Continue to build a closed-loop precision medicine covering the entire cancer cycle.
On June 19, 2020, Genetron Health was officially listed on the Nasdaq Stock Exchange in New York with the stock code "GTH". In this IPO, Genetron Health issued a total of 16 million American Depository Shares (ADS) at a public offering price of US$16 per share. The total amount of funds raised is approximately US$260 million, achieving the largest IPO of a cancer precision medicine company in the history of the world.
On September 30, 2020, the U.S. FDA granted Genetron Health's (NASDAQ: GTH) high-throughput sequencing (NGS)-based liquid biopsy product HCCscreenTM for early screening of hepatocellular carcinoma as "Breakthrough Device Designation". The gene sequencer GENETRON S2000 and the human 8 gene mutation detection kit were launched.
On June 19, 2020, Genetron Health, a precision medical company, was officially listed on NASDAQ under the stock code of GTH. Genetron Health issued a total of 16 million American Depositary Shares (ADS) for this IPO. At US$16 per share, with a market value of US$1.414 billion, it is currently the largest listed cancer precision medicine company.
=== Sequencing system GENETRON Chef/S5 ===
The Genetron Gene Sequencer GENETRON S5 is a new generation of semiconductor sequencer, which can be equipped with the fully automatic sample feeding system GENETRON Chef. Because of its simple and direct principle, higher degree of automation, and more flexible throughput, it has been used in the field of genetic testing. Widely used, no need for specific modified nucleotides, lasers or optical detection equipment, extremely fast detection, accurate sequencing reactions can be completed within 2.5 hours; with automated library building instruments and modular loading design, manual operation is less than 45 minutes; Adapted to 5 chips, high and low throughput, to meet various clinical testing needs; with Genetron's patented one-step tumor detection reagents, it can realize the detection of various tumors such as central nervous system tumors and respiratory system tumors; it can be widely used in transcriptome Sequencing, 16-second metagenomic sequencing, miRNA analysis, exome sequencing and many other aspects.
=== Gene sequencer GENETRON S2000 ===
The gene sequencer GENETRON S2000 adopts a brand-new slide system, which can flexibly support a variety of different sequencing modes, and adopts an optimized design of optical and biochemical systems, which can complete the complete sequencing process in a short time, bringing users more streamlined and smooth Sequencing experience.
=== Biochip Reader GENETRON 3D ===
The biochip reader GENETRON 3D is a digital PCR application system specially designed for Chinese clinics. It has absolute quantification (20,000 microwells/chip, detection sensitivity can reach 0.1%), simple operation (1 step transfer, manual time no more than 5 minutes, Report issued within 4 hours), flexible throughput (1-24 samples/detection, free control of throughput), wide application (quantification of rare mutations, copy number variation analysis, pathogen detection and load analysis, etc.).
=== Human IDH1/TERT mutation detection kit ===
Human IDH1 gene mutation detection kit and human TERT gene promoter mutation detection kit use ARMS-qPCR (mutation block amplification system-polymerase chain reaction) technology, based on real-time fluorescent PCR platform, combined with specific primers and Taqman probe Needle (fluorescent labeled probe) two technologies. This technology has the characteristics of high specificity, high sensitivity, short time-consuming, intuitive results, low cost and simple operation. At present, the ARMS-qPCR method has become one of the important technologies for individualized molecular detection of tumors in the world.
=== Human 8-gene mutation combined detection kit ===
The Human 8 Gene Mutation Joint Detection Kit is Genetron Health's first lung cancer clinical diagnosis kit based on the original "one-step" patented technology and approved by the NMPA. Only 20ngDNA and 50ngRNA can be used to detect 8 genes closely related to targeted therapy in patients with non-small cell lung cancer: EGFR / ALK / ROS1 / BRAF / KRAS / HER2 / MET / PIK3CA, among which the types of gene mutations that can be detected Including point mutation, insertion/deletion and gene fusion.
Category:Pharmaceutical companies of China
Category:Pharmaceutical companies established in 2013
Category:Companies of China 
Category:Cancer precision medicine company